341 related articles for article (PubMed ID: 19172544)
1. Elevated level of plasma vascular endothelial growth factor after gonadotropin-releasing hormone agonist treatment for leiomyomata.
Takeda T; Osuga K; Miyake A; Wakabayashi A; Morishige K; Kimura T
Gynecol Endocrinol; 2008 Dec; 24(12):724-6. PubMed ID: 19172544
[TBL] [Abstract][Full Text] [Related]
2. Changes of plasma vascular endothelial growth factor level after uterine artery embolisation for leiomyomata.
Takeda T; Osuga K; Morishige K; Tasaka K; Nakamura H; Murata Y
BJOG; 2005 Oct; 112(10):1437-9. PubMed ID: 16167953
[TBL] [Abstract][Full Text] [Related]
3. [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone].
Zeng C; Gu M; Huang H
Zhonghua Fu Chan Ke Za Zhi; 1998 Aug; 33(8):490-2. PubMed ID: 10806751
[TBL] [Abstract][Full Text] [Related]
4. Uterine artery embolization of large fibroids: comparative study of procedure with and without pretreatment gonadotropin-releasing hormone agonists.
Kim MD; Lee M; Lee MS; Park SI; Wonq JY; Lee DY; Lee KH
AJR Am J Roentgenol; 2012 Aug; 199(2):441-6. PubMed ID: 22826410
[TBL] [Abstract][Full Text] [Related]
5. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas.
Wang PH; Lee WL; Cheng MH; Yen MS; Chao KC; Chao HT
Taiwan J Obstet Gynecol; 2009 Jun; 48(2):133-7. PubMed ID: 19574174
[TBL] [Abstract][Full Text] [Related]
6. Preoperative administration of GnRH-a plus tibolone to premenopausal women with uterine fibroids: evaluation of the clinical response, the immunohistochemical expression of PDGF, bFGF and VEGF and the vascular pattern.
Di Lieto A; De Falco M; Mansueto G; De Rosa G; Pollio F; Staibano S
Steroids; 2005 Feb; 70(2):95-102. PubMed ID: 15631865
[TBL] [Abstract][Full Text] [Related]
7. Hyalinization and cellular changes in uterine leiomyomata after gonadotropin releasing hormone agonist therapy.
Cohen D; Mazur MT; Jozefczyk MA; Badawy SZ
J Reprod Med; 1994 May; 39(5):377-80. PubMed ID: 7520497
[TBL] [Abstract][Full Text] [Related]
8. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata.
Schlaff WD; Zerhouni EA; Huth JA; Chen J; Damewood MD; Rock JA
Obstet Gynecol; 1989 Dec; 74(6):856-62. PubMed ID: 2511532
[TBL] [Abstract][Full Text] [Related]
9. Gonadotrophin-releasing hormone and magnetic-resonance-guided ultrasound surgery for uterine leiomyomata.
Smart OC; Hindley JT; Regan L; Gedroyc WG
Obstet Gynecol; 2006 Jul; 108(1):49-54. PubMed ID: 16816055
[TBL] [Abstract][Full Text] [Related]
10. The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist.
Rein MS; Friedman AJ; Pandian MR; Heffner LJ
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):388-94. PubMed ID: 2116610
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-releasing hormone agonist pretreatment did not decrease postoperative adhesion formation after abdominal myomectomy in a randomized control trial.
Coddington CC; Grow DR; Ahmed MS; Toner JP; Cook E; Diamond MP
Fertil Steril; 2009 May; 91(5):1909-13. PubMed ID: 18439584
[TBL] [Abstract][Full Text] [Related]
12. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
Takahashi K; Kawamura N; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
[TBL] [Abstract][Full Text] [Related]
13. [A comparative efficacy study of the preoperative use of GnRH agonists in women with uterine fibromyomas].
Nikolov A; Karag'ozov I
Akush Ginekol (Sofiia); 1999; 38(4):38-42. PubMed ID: 10726353
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance guided focused ultrasound surgery of uterine fibroids--the tissue effects of GnRH agonist pre-treatment.
Smart OC; Hindley JT; Regan L; Gedroyc WM
Eur J Radiol; 2006 Aug; 59(2):163-7. PubMed ID: 16740371
[TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
16. Induction of circulating monocyte chemoattractant protein-1 in women with gonadotropin-releasing hormone agonist.
Matsui S; Yasui T; Uemura H; Yamamoto S; Matsuzaki T; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M
J Reprod Immunol; 2011 Aug; 90(2):227-34. PubMed ID: 21726903
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up.
Letterie GS; Coddington CC; Winkel CA; Shawker TH; Loriaux DL; Collins RL
Fertil Steril; 1989 Jun; 51(6):951-6. PubMed ID: 2498132
[TBL] [Abstract][Full Text] [Related]
18. Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium.
Gentry CC; Okolo SO; Fong LF; Crow JC; Maclean AB; Perrett CW
Clin Sci (Lond); 2001 Dec; 101(6):691-5. PubMed ID: 11724658
[TBL] [Abstract][Full Text] [Related]
19. Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues.
van der Spuy ZM; Wood M; Fieggen G; Hendricks MS
S Afr Med J; 1993 Jul; 83(7):510-3. PubMed ID: 8211493
[TBL] [Abstract][Full Text] [Related]
20. Treatment of perimenopausal women with uterine myoma: successful use of a depot GnRH agonist leading to a natural menopause.
Imai A; Sugiyama M; Furui T; Tamaya T
J Obstet Gynaecol; 2003 Sep; 23(5):518-20. PubMed ID: 12963511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
